Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.

Develops and manufactures drugs related to immunology, neurobiology and oncology

Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s Immune System Programming (ISP) technology was developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft. The technology instructs a patient’s cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years. It was founded in 2009 and is headquartered in Seattle, Washington.

Berkeley Lights, Inc. engages in rapid development and commercialization of biotherapeutics and other cell-based products. Its platform captures deep phenotypic, functional and genotypic information for tens of thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. It operates through the following geographical segments: North America, Asia Pacific, and Europe. The company was founded by Igor Y. Khandros, William H. Davidow, Michael E. Marks, and Ming C. Wu on April 5, 2011 and is headquartered in Emeryville, CA.

BioFactura has developed the StableFast™ Biomanufacturing Platform, a novel system to rapidly generate stable NS0 cell lines for biopharmaceutical manufacturing. The elements of this system include a chemically-defined, serum- and cholesterol-free production medium and pre-adapted parental cells, modular expression vectors that utilize a patented selection strategy, and a proprietary growth supplement that permits rapid generation and cloning of cell lines. This platform is simple to use, fast, and productive. A clonal production cell line can be developed and scaled up to yield over one gram of product in less than eight weeks.

Geneius Biotechnology is a T cell immunotherapy company focused on therapies for cancer. There is growing evidence for the potential of T cell immunotherapy for successful treatment of cancer patients. Our proprietary approach is distinct and unique from other T cell immunotherapy approaches and promotes the surveillance and destruction of cancer cells by the immune system. Through a transformative academic collaboration we are rapidly translating products from bench to bedside. We are currently developing products for both hematologic and solid cancers through our academic collaboration and expect to start clinical trials by the end of the year.

ImmunoQure AG rare natural antibodies derived from patients for patients. ImmunoQure AG is a young biotech company spearheading the research and development of human-derived antibodies (HD-MABs) for the treatment of human diseases. Through our unique access to rare patient populations, we are able to identify patients harboring naturally optimized antibodies against key drug targets that are involved in preventing a number of human diseases.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Micron manufactures DRAM components and modules and NAND Flash. For more than 30 years, Micron’s teams of dreamers, visionaries, and scientists have redefined innovation—designing and building some of the world’s most advanced memory and semiconductor technologies. They develop the technologies that transform what's possible. In fact, you likely use their memory every day—in products from computing, networking, and server applications, to mobile, embedded, consumer, automotive, and industrial designs. As one of the most prolific patent holders in the world they continually rethink, recast, and advance new ideas to bring innovation to broader markets and find ways their technology can inspire new applications or make fundamental improvements to existing designs. Their roots are in memory, the core strength of their business. As they look toward the future, they’ll continue to build on their past achievements by leveraging the synergies between their core memory business and diversified products and technologies that help drive innovation and growth in new markets.

Peking Union Medical College Hospital, also known as Beijing Xiehe Hospital (Chinese: 北京协和医院), is a renowned general hospital in Beijing, China. It was founded in 1921 by Rockefeller Foundation and is affiliated to both Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS). During the Cultural Revolution, it was renamed the "Anti-imperialist Hospital".

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Takeda Vaccines, Inc., a subsidiary of Takeda Pharmaceutical Co., Ltd., is an American company located in Bozeman, MT. The firm provides biological research and development services.

AIMM Therapeutics BV develops therapeutic antibodies for the treatment of cancer and infectious diseases. Its antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of antibodies from humans or animals. The company was founded by Donald Kalff and Hergen Spits in 2004 and is headquartered in Amsterdam, the Netherlands.

Hunan Yuanpin Cell Biotechnology Co., Ltd., established on 2015-06-29, Business scope includes biological resources,Stem cell and immune cell storage and biotransformation medical technology services;Wholesale of biological products;Biotechnology Extension Services;medicine,Internet transaction service for medical devices;research and development,Incubation and Transformation;Project Incubation;business incubation;Innovation and Entrepreneurship Incubation Base;Hospital Operations and Management;Medical device technology promotion service;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of;Sub-health intervention technology research;Sub-health intervention technology promotion;Medical laboratory technical service;Biological product,biological reagent,Health products,cosmetic,Class II medical device,Research and development of three types of medical devices;Biological product,biological reagent,cosmetic,Class II medical device,Production of Class III Medical Devices;Biological product,biological reagent,Health products,cosmetic,Class II:6864Sales of medical hygiene materials and dressings;blood products,manufacturing of biopharmaceuticals;Research on new specialty drugs and,Sub-health intervention technology,Development of medical testing technology;Class II medical device,Wholesale of Class III Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.